



**Press Release:**

April 1, 2013 3:00 PM EDT

**Jasco Pharmaceuticals to Present its Preclinical PIM Inhibitor Program at the American Association for Cancer Research Annual Meeting**

Woburn, MA, April 1, 2013 – [Jasco Pharmaceuticals, LLC](#) announced that preclinical data on its PIM inhibitor program would be presented at the American Association for Cancer Research (AACR) Annual Meeting 2013 to be held on April 6-10 in Washington, DC.

The poster entitled “PIM2 Inhibitor as a Targeted Therapy for the Treatment of Multiple Myeloma Patients with Specific Genetic Signatures” will be presented on Sunday, April 7, 2013 from 1:00 PM - 5:00 PM. The poster session is titled, “Experimental and Molecular Therapeutics 8” in Exhibit Hall A-C, Poster Section 43, and Abstract Number: 1049. The results will include data generated in collaboration with the [Roswell Park Cancer Institute](#) in Buffalo, NY.

About Pim Kinases

**Pim kinases** are an exciting class of serine/threonine protein kinases with a structurally unique ATP binding pocket incorporated in all three isoforms (Pim-1, Pim-2 and Pim-3). The Pim kinases are key components of the JAK/STAT signaling pathway and regulate cancer cell survival, providing an important set of therapeutic targets for the treatment of various hematological malignancies and solid tumors. Jasco Pharmaceuticals has developed structurally novel, potent, small molecule pan-PIM inhibitors with skewed potency towards PIM2. Jasco’s preclinical candidate has demonstrated selective potency for multiple myeloma cell lines with the t(14;16) and t(4;14) translocations, which are known markers for poor prognosis and proven efficacious in the corresponding xenograft mouse models.

About Jasco Pharmaceuticals

**Jasco Pharmaceuticals, LLC** is a privately held, pre-clinical stage biopharmaceutical company focused on the development of small molecule oncology therapeutics. Jasco was founded with a core expertise in high speed medicinal chemistry providing a launching point for a chemical genomics approach to the discovery of selective protein kinase inhibitors. The company’s vision is to rapidly and effectively develop pre-clinical oncology candidates that are progressed through the clinical development process by means of strategic partnerships.

For more information about Jasco Pharmaceuticals, please visit [www.jascopharma.com](http://www.jascopharma.com) or call Carmen M. Baldino, Ph.D., at 339-227-6822 Ext. 12.

### About Roswell Park Cancer Institute

The mission of **Roswell Park Cancer Institute (RPCI)** is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs.

For more information, visit RPCI's website at <http://www.roswellpark.org>, call 1-877-ASK-RPCI (1-877-275-7724) or email [askrpci@roswellpark.org](mailto:askrpci@roswellpark.org).

### About Professor Kelvin Lee's Research

Kelvin Lee, MD, is an internationally recognized leader in the field in multiple myeloma and dendritic cell biology who joined the Roswell Park Cancer Institute in October 2006. His work focuses on both basic and clinical research aspects of immunology and hematological oncology. His laboratory has a long standing interest in role of CD28 in immune responses and multiple myeloma biology, and published in Blood in 2007 one of the first characterization of CD28's pro-survival function in multiple myeloma. Since that time he has continued to characterize the role of CD28 in myeloma cell survival and resistance to chemotherapy.